Stevanato Group's Mauro Stocchi Sells 6,586 Shares
Chief Business Strategy Officer Mauro Stocchi sold shares in Stevanato Group on June 9.
Key Points
- Mauro Stocchi, Chief Business Strategy Officer at Stevanato Group, sold 6,586 shares on June 9, 2026.
- Stevanato Group's stock on the NYSE traded near $18.39 on Friday, with a market cap of $5.02 billion and a P/E ratio of 31.71.
- TD Cowen initiated coverage with a 'buy' rating and a $25 target on June 16, 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Mauro Stocchi, the Chief Business Strategy Officer at Stevanato Group S.p.A. (NYSE:STVN), sold 6,586 shares of the company on June 9, 2026. The transaction did not occur under a pre-planned Rule 10b5-1 trading plan.
Stevanato Group S.p.A. Stock Down 12.6%
Shares of NYSE:STVN traded near $18.39 on Friday. Stevanato Group, a leader in the healthcare sector, has a market capitalization of approximately $5.02 billion. The company's price-to-earnings ratio stands at 31.71, with a forward P/E of 21.95, indicating investor expectations for future earnings growth. The stock's 52-week range is between $12.89 and $28.00, with a 50-day moving average of $17.39 and a 200-day moving average of $19.57.
$STVN stock price
Daily closing prices, year to date. Not investment advice.
Insider Buying and Selling at Stevanato Group S.p.A.
In addition to Mauro Stocchi's sale, several other insiders have been active. On June 15, 2026, insiders Flynn Karen, Federici William, Balachandran Madhavan, and Morel Donald Jr. each sold 1,493 shares at an average price of $17.09. Meanwhile, on June 12, William Federici bought 4,975 shares, and Marco Dal Lago, the Chief Financial Officer, acquired 2,356 shares.
Analysts Set New Price Targets
Analyst activity has been robust around Stevanato Group. On June 16, 2026, TD Cowen initiated coverage with a 'buy' rating and a price target of $25. Earlier, on June 2, Wolfe Research assumed coverage with a 'buy' rating and a $21 target. The consensus among analysts is a 'buy' recommendation, with an average price target of $24.45.
About Stevanato Group
Stevanato Group S.p.A. designs and produces medical instruments and supplies, serving the biopharmaceutical and healthcare industries globally. Based in Piombino Dese, Italy, the company offers solutions such as pre-fillable syringes, drug delivery systems, and diagnostic tools. Founded in 1949, it employs over 6,000 people and is led by CEO Mr. Franco Stevanato.
Bottom Line
Mauro Stocchi's recent sale of shares in Stevanato Group comes amid active insider trading and a series of new analyst ratings. Investors keep a close eye on such insider activities and analyst opinions as potential indicators of a company's future performance. However, it's important to remember that these insider transactions are disclosed after the fact and may not reflect current positions.
Get Stevanato Group S.p.A. alerts
New 13F filings, insider trades, and analyst moves on $STVN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.